Skip to main content
John Vetto, MD, General Surgery, Portland, OR

JohnTysonVettoMD

General Surgery Portland, OR

Surgical Oncology (Other than Breast)

Associate Professor of Surgery, Oregon Hlth & Sci Univ

Dr. Vetto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vetto's full profile

Already have an account?

  • Office

    3181 SW Sam Jackson Park Rd
    Portland, OR 97239
    Phone+1 503-494-5501

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Surgery, 1984 - 1989
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Surgery, 1982 - 1984
  • Oregon Health and Science University School of Medicine
    Oregon Health and Science University School of MedicineClass of 1982

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 1991 - 2025
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2010-2014
  • America's Top Doctors for Cancer Castle Connolly, 2009-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Microsatellitosis in Patients with Melanoma  
    Richard L White, Mark B Faries, Stanley P Leong, Andrew J Sinnamon, Dale Han, Jane L Messina, Barbara A Pockaj, Giorgos C Karakousis, Edmund K Bartlett, John T Vetto, ..., Annals of Surgical Oncology

Press Mentions

  • Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating That Its DecisionDx-Melanoma Test Can Inform Sentinel Lymph Node Biopsy Decisions
    Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating That Its DecisionDx-Melanoma Test Can Inform Sentinel Lymph Node Biopsy DecisionsJanuary 30th, 2019
  • Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study
    Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published StudyJanuary 7th, 2019
  • Independent Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions in Melanoma
    Independent Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions in MelanomaMarch 21st, 2018
  • Join now to see all

Professional Memberships